Human βc Receptor Expression in Japanese and Caucasian Participants
Research type
Research Study
Full title
Assessment of Human Beta Common (βc) Receptor Expression on Neutrophils, Monocytes, Eosinophils, Basophils and pDCs in Japanese and Caucasian Participants by Flow Cytometry
IRAS ID
320142
Contact name
Kristee Martin
Contact email
Sponsor organisation
CSL Innovation - Research and Clinical Bioanalytics
Duration of Study in the UK
0 years, 1 months, 11 days
Research summary
The aim of this study is to compare the relative expression levels and potential binding efficiencies of human beta common (βc) receptors on the cell surface of immune cells (neutrophils, monocytes, eosinophils, basophils and plasmacytoid dendritic cells [pDCs]) collected from healthy Japanese participants and age- and sex-matched Caucasian participants. Human βc receptor is a receptor to which pro-inflammatory substances bind to exhibit their effect. This study will involve a single research site, Richmond Pharmacology Ltd, who will consent and collect whole blood and urine from 20 Japanese healthy participants and 20 Caucasian healthy participants. Whole blood samples will be collected and sent directly to a testing laboratory where the measurement of βc receptor expression level on neutrophils, monocytes, eosinophils, basophils and pDCs will be performed by flow cytometry (laboratory technique). The data generated from this study will be used to guide the clinical development of CSL311 which is a new drug as a treatment for severe asthma patients.
Urine samples will be collected and may be used for additional exploratory tests to compare soluble urine protein differences between healthy Japanese and Caucasian populations for this or other sponsor's projects.
No administration of an investigational or registered product to participants will occur during the study.REC name
South West - Central Bristol Research Ethics Committee
REC reference
22/SW/0170
Date of REC Opinion
17 Nov 2022
REC opinion
Favourable Opinion